Search

Arvinas Inc

Suletud

SektorTervishoid

9.32 -0.43

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.03

Max

9.36

Põhinäitajad

By Trading Economics

Sissetulek

227M

169M

Müük

234M

250M

P/E

Sektori keskmine

35.385

57.371

Aktsiakasum

2.58

Kasumimarginaal

67.841

Töötajad

246

EBITDA

216M

159M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+59.83% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

74M

594M

Eelmine avamishind

9.75

Eelmine sulgemishind

9.32

Uudiste sentiment

By Acuity

47%

53%

145 / 340 Pingereas Healthcare

Arvinas Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21. aug 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20. aug 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19. aug 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17. aug 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14. aug 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13. aug 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11. aug 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10. aug 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7. aug 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6. aug 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5. aug 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4. aug 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3. aug 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31. juuli 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29. juuli 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28. juuli 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24. juuli 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22. juuli 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21. juuli 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Võrdlus sarnastega

Hinnamuutus

Arvinas Inc Prognoos

Hinnasiht

By TipRanks

59.83% tõus

12 kuu keskmine prognoos

Keskmine 14.96 USD  59.83%

Kõrge 21 USD

Madal 8.68 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Arvinas Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

5

Osta

6

Hoia

0

Müü

Sentiment

By Acuity

145 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat